Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/121515
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMassari, Caio M.-
dc.contributor.authorLópez-Cano, Marc-
dc.contributor.authorNúñez, Fabiana-
dc.contributor.authorFernández Dueñas, Víctor-
dc.contributor.authorTasca, Carla I.-
dc.contributor.authorCiruela Alférez, Francisco-
dc.date.accessioned2018-04-12T11:59:04Z-
dc.date.available2018-04-12T11:59:04Z-
dc.date.issued2017-10-04-
dc.identifier.issn1663-9812-
dc.identifier.urihttp://hdl.handle.net/2445/121515-
dc.description.abstractGuanosine (GUO) is a guanine-based purine nucleoside with important trophic functions and promising neuroprotective properties. Although the neuroprotective effects of GUO have been corroborated in cellular models of Parkinson's disease (PD), its efficacy as an antiparkinsonian agent has not been fully explored in PD animal models. Accordingly, we evaluated the effectiveness of GUO in reversing motor impairments in several rodent movement disorder models, including catalepsy, tremor, and hemiparkinsonism. Our results showed that orally administered GUO antagonized reserpine-mediated catalepsy, reduced reserpine-induced tremulous jaw movements, and potentiated the number of contralateral rotations induced by L-3,4-dihydroxyphenylalanine in unilaterally 6-hydroxidopamine-lesioned rats. In addition, at 5 and 7.5 mg/kg, GUO inhibited L-DOPA-induced dyskinesia in rats chronically treated with a pro-dopaminergic agent. Overall, we describe the therapeutic potential of GUO, which may be effective not only for reversing parkinsonian motor impairments but also for reducing dyskinesia induced by treatment for PD.-
dc.format.extent8 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherFrontiers Media-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3389/fphar.2017.00700-
dc.relation.ispartofFrontiers in Pharmacology, 2017, vol. 8, p. 700-
dc.relation.urihttps://doi.org/10.3389/fphar.2017.00700-
dc.rightscc-by (c) Massari, Caio M. et al., 2017-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es-
dc.sourceArticles publicats en revistes (Patologia i Terapèutica Experimental)-
dc.subject.classificationMalaltia de Parkinson-
dc.subject.classificationTrastorns motors-
dc.subject.classificationTremolor-
dc.subject.classificationNucleòsids-
dc.subject.otherParkinson's disease-
dc.subject.otherMovement disorders-
dc.subject.otherTremor-
dc.subject.otherNucleosides-
dc.titleAntiparkinsonian efficacy of guanosine in rodent models of movement disorder-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec679448-
dc.date.updated2018-04-12T11:59:04Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid29046640-
Appears in Collections:Articles publicats en revistes (Patologia i Terapèutica Experimental)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
679448.pdf941.34 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons